These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8702361)

  • 61. Case study of the anemic patient: epoetin alfa--focus on sexual function.
    Zarifian A
    ANNA J; 1994 Oct; 21(6):368-71. PubMed ID: 7993143
    [TBL] [Abstract][Full Text] [Related]  

  • 62. DOQI Guidelines/fifth in a series. A focus on iron management for better HcTs.
    Nephrol News Issues; 1997 Sep; 11(9):39, 53. PubMed ID: 9348872
    [No Abstract]   [Full Text] [Related]  

  • 63. Anemia management in pediatric dialysis patients. Case study of the anemic patient.
    Currier H
    ANNA J; 1999 Jun; 26(3):349-52. PubMed ID: 10633609
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 65. Time to consider the role of epoetin.
    Zhang Y; Thamer M
    Kidney Int; 2006 May; 69(10):1917; author reply 1917-8. PubMed ID: 16688199
    [No Abstract]   [Full Text] [Related]  

  • 66. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients.
    Delano BG
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):14-8. PubMed ID: 2757025
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Epoetin alfa: a keystone in the treatment of the anemic patient with chronic renal failure. Proceedings of a symposium held April 27, 1989, by the Keystone Chapter of ANNA, Valley Forge, Pennsylvania.
    Binkley L; Gallagher N; Latham D; Nichols E; Prowant B
    ANNA J; 1989 Aug; 16(5):341-51. PubMed ID: 2673076
    [No Abstract]   [Full Text] [Related]  

  • 68. Case management of the anemic patient. Epoetin alfa: focus on pediatric dialysis patients.
    Gilman C
    ANNA J; 1992 Oct; 19(5):496-7. PubMed ID: 1456798
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
    Johnson CA; Rosowski E; Zimmerman SW
    Adv Perit Dial; 1992; 8():444-7. PubMed ID: 1361844
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Erythropoietin 1991--an overview.
    Eschbach JW
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):3-9. PubMed ID: 1928076
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Analysis of initial resistance of erythropoiesis to treatment with recombinant human erythropoietin. Results of a multicenter trial in patients with end-stage renal disease.
    Kühn K; Nonnast-Daniel B; Grützmacher P; Grüner J; Pfåffl W; Baldamus CA; Scigalla P
    Contrib Nephrol; 1988; 66():94-103. PubMed ID: 3292152
    [No Abstract]   [Full Text] [Related]  

  • 73. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
    Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
    Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Myocardial disease, anemia, and erythrocyte-stimulating proteins in chronic kidney disease.
    Foley RN
    Rev Cardiovasc Med; 2005; 6 Suppl 3():S27-34. PubMed ID: 16340936
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease.
    Kimel M; Leidy NK; Mannix S; Dixon J
    Value Health; 2008; 11(1):57-75. PubMed ID: 18237361
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Human recombinant erythropoietin in the treatment of anaemia in chronic haemodialysis patients.
    Sulková S; Kvasnicka J; Kasl M; Kozlová J; Podrouzek P; Bartûsková J; Válek A
    Czech Med; 1990; 13(2-3):98-106. PubMed ID: 2245762
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Epoetin alfa: patient management issues and development through recombinant DNA technology. Part 1: Focus on Epoetin alfa patient management and recombinant DNA technology.
    Latham D; Nichols E
    ANNA J; 1990 Aug; 17(4):311-4. PubMed ID: 2396857
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Case management of the anemic patient. Focus on hemodynamics.
    Pugh M; Saylor G
    ANNA J; 1991 Jun; 18(3):316-7. PubMed ID: 2064457
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Epoetin alfa--focus on nursing case management. Case study of the anemic patient.
    White RB
    ANNA J; 1996 Jun; 23(3):326-9. PubMed ID: 8716992
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Epoetin alfa--focus on nutritional therapy. Case study of the anemic patient.
    College J
    ANNA J; 1996 Aug; 23(4):416-9. PubMed ID: 8900689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.